Concepedia

Publication | Open Access

Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial

DOIFull Paper Access

80

Citations

52

References

2007

Year

P. Sonneveld, Bronno van der Holt, Christine M. Segeren, Edo Vellenga, Alexandra Croockewit, G. Verhoef, Jan J. Cornelissen, M Schaafsma, Marinus H. J. van Oers, P. W. Wijermans,
Haematologica

Abstract

Double, intensive treatment resulted in a better CR rate, event-free survival and progression-free survival but not overall survival compared to single non-myeloablative treatment in previously untreated patients with multiple myeloma.

References

YearCitations

Page 1